Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/06/25
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business UpdatePRNewsWire • 04/29/25
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent LitigationPRNewsWire • 03/27/25
Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to TradeZacks Investment Research • 03/05/25
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 03/04/25
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatePRNewsWire • 03/04/25
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business UpdatePRNewsWire • 02/25/25
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect?Zacks Investment Research • 02/03/25
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell DiseasePRNewsWire • 01/22/25
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should KnowZacks Investment Research • 01/17/25